Hiroki Hidejima
Direttore/Membro del Consiglio presso METAREAL CORPORATION
Patrimonio netto: 1 M $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Shunichi Ishimura | M | 74 |
THANN Natural KK
| 12 anni |
Yoko Jacobson | F | 56 | 20 anni | |
Junichi Goishi | M | 59 | 20 anni | |
Takashi Tsutsui | M | 73 | 3 anni | |
Taketo Arakawa | M | 33 | 4 anni | |
Kazuhiro Tokimasa | M | 64 | 3 anni | |
Takahiro Fujita | M | 48 |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | - |
Masayuki Fukumura | M | - |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | 16 anni |
Hiromu Ozaki | M | - |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | 9 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Takashi Tsuzumitani | M | 61 | - | |
Takahiro Okuyama | M | 55 | - | |
Hiroko Ukegawa | F | 57 | - | |
Sadatomo Miyazaki | M | 51 | - | |
Terufumi Watanabe | M | 40 | - | |
Yukitoshi Funo | M | 77 |
Kobe University Graduate School of Business Administration
| 4 anni |
Akira Kono | M | - | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Giappone | 16 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Hiroki Hidejima
- Contatti personali